Advocate Bone Marrow Transplant and Cellular
Therapy Program at Lutheran General Hospital
Center for Advance Care
1700 Luther Lane, #G-123
Park Ridge, IL 60068
Direct phone: 847-723-4400
Total transplants by cell source
- Marrow: 6
- PBSC: 67
- Cord Blood: 1
- Autologous (PBSC or Marrow): 121
About the center
Advocate Bone Marrow Transplant and Cellular Therapy Program at Advocate Lutheran General Hospital provides adult autologous, matched related-allogeneic, matched un-related allogeneic transplants, haploidentical, as well as CBU transplantation for hematological malignancies such as Leukemia, Myeloma and Lymphoma and non-malignancies as Aplastic Anemia and Sickle Cell Anemia. The program offers Immune Effector Cellular therapies such as DLI, CAR T-cell therapy, Bi-specific T-cell engagers. Collectively, our physicians have more than 65 years of transplant experience, and we offer expert and personalized care with a dedicated team of APPs, nurses, coordinators, pharmacists, nutritionists, and physical and occupational therapists.
This center has been performing allogeneic transplants since 1994 and has been an NMDP/Be The Match transplant center since January 2015.
Adult - Syed Haider, Leonard Klein, Tulio Rodriguez
Marrow/PBSC, single cord, and double cord
Cord blood transplants performed on
Other programs and services
We have discounted housing and nearby hotels. There is area transportation and special services available to help support patient and family members during the transplant process. We have a Cancer Survivorship Center which provides free Social Work and Counseling Services to patients and their care-givers. We have a state-of-the-art Apheresis & Collection center. We have Advanced Practice Providers and BMT Nurse Navigators to assist patients along their journey.
Overall center survival
Patient survival information for this center
This center's actual 1-year survival results are below the expected rate for this center.
The survival information we have for this center includes ONLY:
- Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2018, 2019, 2020, and
- Who had their transplant at a U.S. transplant center, and
- Who had follow-up information provided by the transplant center for analysis
For this center, we have survival information for 103 patients.
The actual 1-year survival of these patients is 54.4%.
Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 62.4% and 79.0%.
For help with understanding these statistics, please see Understanding Transplant Outcomes.
For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.
Transplants reported (From January 1, 2020 to December 31st, 2021 as reported by the centers)
|Both marrow & PBSC
Transplants by disease
Number of transplants by age reported from January 1, 2020 to December 31st, 2021 (includes marrow, PBSC and cord blood)
Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.
Centers are not required to report autologous transplants so the numbers might be incomplete.
More information about transplants for this disease can be found:
Transplant center resources
Transplant center coordinator:
If you have questions about costs and financial services at this center, please call the transplant center's direct phone number.
Be The Match patient navigators
Patient navigators can answer your questions about choosing a transplant center and provide support and education to help you throughout your transplant journey.
Inside the United States: 1 (888) 999-6743
Outside the United States: 1 (763) 406-3410.
(Long distance or international charges may apply.)
No survivorship program information is available. Contact the center for information about post-transplant care.